Baidu
map

Blood:免疫疗法重大突破,CRISPR基因编辑技术为癌症患者带来新曙光

2017-11-20 佚名 medicalxpress

卡迪夫大学的研究人员找到一种方法来刺激T细胞的能力,这为广泛打击癌细胞带来了新的希望。

卡迪夫大学的研究人员找到一种方法来刺激T细胞的能力,这为广泛打击癌细胞带来了新的希望。

使用CRISPR基因组编辑技术可以识别特定的癌细胞,并摧毁它们。卡迪夫大学研究人员表示:“到目前为止,t细胞工程抗癌有两种受体,一种是在实验室中培育的,一种是自己体内自然形成的。由于只有细胞受体空间有限,癌症特异性要求细胞的受体来执行其功能。通常情况下,细胞的受体赢得竞争,并留下“空间”引入癌症特异性受体,这意味着t细胞工程与当前技术没有充分发挥他们猎杀癌细胞的能力。”

研究人员补充说:“我们使用的t细胞基因组编辑没有自己的t细胞受体,因此他们可以使用唯一的受体。因此,与当前的方法比起来,这些细胞可以以成千倍的速度杀死癌细胞。T细胞是免疫系统的一部分,帮助我们对抗细菌和病毒感染,如流感病毒。一些t细胞也能攻击癌细胞,因此,利用人体自身的t细胞抗癌就是免疫疗法的初衷,也正是这种方法正在改变着癌症的治疗。

团队相信改善基因编辑技术将彻底改变癌症免疫疗法的效果,这是前所未有的突破,适用于更广泛,不同类型的癌症。研究人员在报告中指出:“我相信,我们的改善t细胞特异性的方法将引导新一代的临床试验,成为癌症治疗的新目标。”

原始出处:

Mateusz Legut, Garry Dolton, Afsar Ali Mian, et.al. CRISPR-mediated TCR replacement generates superior anticancer transgenic T-cells. Blood

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1744373, encodeId=a84c1e44373d0, content=<a href='/topic/show?id=42a7523823' target=_blank style='color:#2F92EE;'>#CRISPR基因编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5238, encryptionId=42a7523823, topicName=CRISPR基因编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1c35375117, createdName=guguangxiang, createdTime=Tue Mar 06 09:39:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725152, encodeId=aa1c1e25152ab, content=<a href='/topic/show?id=58476021257' target=_blank style='color:#2F92EE;'>#曙光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60212, encryptionId=58476021257, topicName=曙光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=180c33737541, createdName=yangpeizhi, createdTime=Sun Apr 22 02:39:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276055, encodeId=d90812e605515, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289567, encodeId=a1dc128956ec3, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630158, encodeId=7f82163015898, content=<a href='/topic/show?id=d81a4186e3f' target=_blank style='color:#2F92EE;'>#基因编辑技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41867, encryptionId=d81a4186e3f, topicName=基因编辑技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c21466636, createdName=marlenexl, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1744373, encodeId=a84c1e44373d0, content=<a href='/topic/show?id=42a7523823' target=_blank style='color:#2F92EE;'>#CRISPR基因编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5238, encryptionId=42a7523823, topicName=CRISPR基因编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1c35375117, createdName=guguangxiang, createdTime=Tue Mar 06 09:39:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725152, encodeId=aa1c1e25152ab, content=<a href='/topic/show?id=58476021257' target=_blank style='color:#2F92EE;'>#曙光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60212, encryptionId=58476021257, topicName=曙光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=180c33737541, createdName=yangpeizhi, createdTime=Sun Apr 22 02:39:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276055, encodeId=d90812e605515, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289567, encodeId=a1dc128956ec3, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630158, encodeId=7f82163015898, content=<a href='/topic/show?id=d81a4186e3f' target=_blank style='color:#2F92EE;'>#基因编辑技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41867, encryptionId=d81a4186e3f, topicName=基因编辑技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c21466636, createdName=marlenexl, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2018-04-22 yangpeizhi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1744373, encodeId=a84c1e44373d0, content=<a href='/topic/show?id=42a7523823' target=_blank style='color:#2F92EE;'>#CRISPR基因编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5238, encryptionId=42a7523823, topicName=CRISPR基因编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1c35375117, createdName=guguangxiang, createdTime=Tue Mar 06 09:39:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725152, encodeId=aa1c1e25152ab, content=<a href='/topic/show?id=58476021257' target=_blank style='color:#2F92EE;'>#曙光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60212, encryptionId=58476021257, topicName=曙光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=180c33737541, createdName=yangpeizhi, createdTime=Sun Apr 22 02:39:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276055, encodeId=d90812e605515, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289567, encodeId=a1dc128956ec3, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630158, encodeId=7f82163015898, content=<a href='/topic/show?id=d81a4186e3f' target=_blank style='color:#2F92EE;'>#基因编辑技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41867, encryptionId=d81a4186e3f, topicName=基因编辑技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c21466636, createdName=marlenexl, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2017-11-22 yuandd
  4. [GetPortalCommentsPageByObjectIdResponse(id=1744373, encodeId=a84c1e44373d0, content=<a href='/topic/show?id=42a7523823' target=_blank style='color:#2F92EE;'>#CRISPR基因编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5238, encryptionId=42a7523823, topicName=CRISPR基因编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1c35375117, createdName=guguangxiang, createdTime=Tue Mar 06 09:39:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725152, encodeId=aa1c1e25152ab, content=<a href='/topic/show?id=58476021257' target=_blank style='color:#2F92EE;'>#曙光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60212, encryptionId=58476021257, topicName=曙光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=180c33737541, createdName=yangpeizhi, createdTime=Sun Apr 22 02:39:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276055, encodeId=d90812e605515, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289567, encodeId=a1dc128956ec3, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630158, encodeId=7f82163015898, content=<a href='/topic/show?id=d81a4186e3f' target=_blank style='color:#2F92EE;'>#基因编辑技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41867, encryptionId=d81a4186e3f, topicName=基因编辑技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c21466636, createdName=marlenexl, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1744373, encodeId=a84c1e44373d0, content=<a href='/topic/show?id=42a7523823' target=_blank style='color:#2F92EE;'>#CRISPR基因编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5238, encryptionId=42a7523823, topicName=CRISPR基因编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1c35375117, createdName=guguangxiang, createdTime=Tue Mar 06 09:39:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725152, encodeId=aa1c1e25152ab, content=<a href='/topic/show?id=58476021257' target=_blank style='color:#2F92EE;'>#曙光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60212, encryptionId=58476021257, topicName=曙光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=180c33737541, createdName=yangpeizhi, createdTime=Sun Apr 22 02:39:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276055, encodeId=d90812e605515, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289567, encodeId=a1dc128956ec3, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630158, encodeId=7f82163015898, content=<a href='/topic/show?id=d81a4186e3f' target=_blank style='color:#2F92EE;'>#基因编辑技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41867, encryptionId=d81a4186e3f, topicName=基因编辑技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c21466636, createdName=marlenexl, createdTime=Wed Nov 22 11:39:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]

相关资讯

别再黑处女座啦!他们也是身不由己

你对于处女座的印象是什么?很多人觉得他们有洁癖、斤斤计较,像一个重度强迫症患者……爱研究星座的人们把处女座黑得体无完肤,但是实际上,科学家们研究发现,强迫症是一种人类基因变异的表达哦!强迫症相关人类基因变异找到英国《自然·通讯》杂志近日在线发表的一篇遗传学论文报告称,科学家成功鉴别出与强迫症(OCD)相关的人类基因变异,找到了受这些变异影响的基因及神经通路。分离和表征这些基因,将帮助我们理解这种疾

Nat Genet:在猴子身上的研究将帮助人类找到对抗HIV的方法!

在非洲和加勒比地区发现的猴子是疟疾免疫缺陷病毒(SIV)中最丰富的天然宿主,这是与艾滋病毒/艾滋病有着亲密关系的。

JAMA:胰腺癌患者存活时间竟由这四种基因决定!

https://www.ncbi.nlm.nih.gov/pubmed/?term=Association+of+Alterations+in+Main+Driver+Genes+With+Outcomes+of+Patients+With+Resected+Pancreatic+Ductal+Adenocarcinoma

两个大叔的健康故事:你没有强大的基因,你就老老实实的治病

两个油腻大叔的健康故事,如果你没有强大的遗传基因,你就踏踏实实的健康生活。今天我给大家讲两个“油腻”中年大叔的健康故事,两个人一个是我的同乡,一个是我的朋友。先说我的同乡A君。国庆假期的最后一天,他就感觉胸闷不舒服,他知道自己的生活习惯不好,估计心脏可能出问题了,于是和家人说好第二天节后上班去医院检查。没成想到了半夜,他突然感觉心前区剧烈疼痛,为压榨性疼痛,疼痛难忍,同时伴有喘不上气,呼吸困难。家

J NUTRIGENET NUTRIGE :儿童挑食与娇生惯养无关,只因基因在搞鬼

科学家最近发现,儿童挑食与娇生惯养无关,两种基因突变可能是引发他们挑食的主要原因;至于孩子不敢尝试从未吃过的食物,78%是受到遗传基因影响,剩下22%是由外界环境因素造成的。

NCRI Cancer Conferen:这种新的技术可以使食道癌提前八年被检测出来!

根据利物浦国家癌症研究所(NCRI)癌症会议上发表的一项新研究,一项新的基因检测可以帮助诊断食管癌长达8年,然后症状将出现在高风险人群中。

Baidu
map
Baidu
map
Baidu
map